# Cross-Review Prompt — Codex reviews Claude (ABS Walk Spike R3)

You completed Round 3 of CalledThird's "ABS Walk Spike" research as Agent B (Codex). Your work is in `codex-analysis-r3/`. Your headlines:

- **H1 triangulated: +27.0% [+5.7%, +56.9%]** (Method A=200, Method C=100×10)
- **H2: 9 ML-stable adapters**
- **H3: ρ=−0.258 (p<0.0001); 5 hurt + 2 helped stable**
- Calibration audit: 343/1000 H2 GBMs OOB calibration bin >5pp; H1 had 3/1200 over 5pp

Claude's R3 is at `claude-analysis-r3/`. Their headlines:

- **H1 triangulated: +14.5% [+0.2%, +70.1%]** (3 methods: A=−58.6%, B=+38.3%, C=+14.5%)
- **H2: 0 of 367 pitchers cleared ≥80% bootstrap stability.** Max 58.5%. Publishable null.
- **H3: ρ=−0.282 (p<0.0001); 1 hurt (Finnegan +11.4pp) + 3 helped (O'Brien -8.3pp, Doval -7.5pp, Miller -4.3pp)**

## Your task

Read Claude's R3:
- `claude-analysis-r3/REPORT.md`
- `claude-analysis-r3/findings.json`
- `claude-analysis-r3/READY_FOR_REVIEW.md`
- Their code: `h1_triangulation.py`, `h2_adapter_leaderboard.py`, `h3_archetype_interaction.py`

Write `/Users/haohu/Documents/GitHub/calledthird/research/abs-walk-spike/reviews/r3-codex-review-of-claude.md` (~1000 words).

## Priority focus areas

### 1. H1 triangulation convergence
- Claude's Method A (−58.6%) is dramatically negative — that was the contested R2 result that you and the cross-review flagged as a stress test. Have they kept it as a stress test or are they reporting it as the headline?
- Their headline is the *median* of three methods (+14.5%) with the *widest of three CIs* as the editorial CI (Method B's [+0.2, +70.1]). Is this the right way to triangulate, or does it under-state the +27% you got?

### 2. H2 divergence — Claude 0 vs your 9 (PRIORITY)
- Did Claude apply a stricter stability threshold? Same magnitude thresholds?
- Did Claude's per-pitcher Beta-Binomial framework produce wider CIs than your LightGBM ensemble (making fewer pitchers clear filters)?
- Of your 9 named adapters, do any appear in Claude's top-15 (their `h2_full_pitcher_leaderboard.parquet`)?
- Should the article publish 9 names, 0 names, or only the cross-method intersection (likely 0-3 names)?

### 3. H3 archetype convergence
- Spearman correlations virtually identical (−0.258 vs −0.282) — strong convergence.
- Cross-method named-pitcher intersection: which appear in BOTH lists?
- The Bayesian slope of −1.40pp/unit gives a magnitude interpretation. Is your SHAP interaction effect (+0.00243 vs null +0.00333) similar in magnitude when properly scaled?

### 4. Methodology audit on Claude
- Did Claude actually run 100×10 bootstrap-of-bootstrap, or did they shortcut?
- Their Method A continuation-model fix: "0 of 46,755 PAs hit truncation in the new replay" — is that plausible? Or did the new continuation model just inherit a different bias?
- Their archetype proxy: arsenal-weighted whiff-rate percentile for stuff+, mean(zone-rate, -walk-rate) for command+. Same as yours?

### 5. The R2 Claude −64.6% artifact
- Both of you now agree R2 Claude was an artifact (the observed-outcome backstop). Confirm this is the right read.

## Format

```markdown
# Round 3 — Codex's Review of Claude

## Headline assessment
{One paragraph: do you trust Claude's R3 conclusions? Convergence/divergence pattern?}

## Critical issues (potential blockers)
1. {File:line reference}
2. ...

## The H2 divergence (priority — their 0 vs your 9)
{Reconciliation: who's right? Article publishes what?}

## The H1 cross-agent triangulation
{Your 3 + their 3 = 6 estimates. Cross-agent median + editorial CI.}

## H3 cross-method intersection
{Named pitchers in BOTH stable lists — publication-locked.}

## Methodology concerns
1. ...

## Things Claude got right
1. ...

## Recommendation for the comparison memo
{One paragraph: A-tier verdict on the piece overall.}
```

Target ~1000 words. Reference file:line. Deliverable: `reviews/r3-codex-review-of-claude.md`. Only file you write. Read-only on analysis dirs.
